4.7 Article

A Novel Method of 18F Radiolabeling for PET

Journal

JOURNAL OF NUCLEAR MEDICINE
Volume 50, Issue 6, Pages 991-998

Publisher

SOC NUCLEAR MEDICINE INC
DOI: 10.2967/jnumed.108.060418

Keywords

bispecific antibody; cancer; CEACAM5; F-18; pretargeting; molecular imaging; PET

Funding

  1. NIH [1 R43 EB003751-01A1]
  2. National Institute of Biomedical Imaging and Bioengineering

Ask authors/readers for more resources

Small biomolecules are typically radiolabeled with F-18 by binding it to a carbon atom, a process that usually is designed uniquely for each new molecule and requires several steps and hours to produce. We report a facile method wherein F-18 is first attached to aluminum as (AlF)-F-18, which is then bound to a chelate attached to a peptide, forming a stable (AlF)-F-18-chelate-peptide complex in an efficient 1-pot process. Methods: For proof of principle, this method was applied to a peptide suitable for use in a bispecific antibody pretargeting method. A solution of AlCl3 center dot 6H(2)O in a pH 4.0 sodium-acetate buffer was mixed with an aqueous solution of F-18 to form the (AlF)-F-18 complex. This was added to a solution of IMP 449 (NOTA-p-Bn-CS-D-Ala-D-Lys(HSG)-D-Tyr-D- Lys(HSG)-NH2) (NOTA-p-Bn-CS is made from S-2-(4-isothiocyanatobenzyl)- 1,4,7-triazacyclononane-1,4,7-triacetic acid; HSG is histamine-succinyl-glycine) and heated to 100 degrees C for 15 min. In vitro and in vivo stability and targeting ability of the (AlF)-F-18-IMP 449 were examined in nude mice bearing LS174T human colonic tumors pretargeted with an anti-CEACAM5 bispecific antibody (TF2). Results: The radiolabeled peptide was produced in 5%-20% yield with an estimated specific activity of 18,500-48,100 GBq (500-1,300 Ci)/mmol. The (AlF)-F-18-IMP 449 was stable for 4 h in serum in vitro, and in animals, activity isolated in the urine 30 min after injection was bound to the peptide. Nonchelated (AlF)-F-18 had higher tissue uptake, particularly in the bones, than the chelated (AlF)-F-18-IMP 449, which cleared rapidly from the body by urinary excretion. Tumor uptake was 30-fold higher with TF2-pretargeted (AlF)-F-18-IMP 449 than with the peptide alone. Dynamic PET showed tumor localization within 30 min and rapid and thorough clearance from the body. Conclusion: The ability to bind highly stable (AlF)-F-18 to metal-binding ligands is a promising new labeling method that should be applicable to a diverse array of molecules for PET.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available